Christopher J Melani
ECOG-ACRIN Cancer Research Group · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher J Melani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:16 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06649812 · Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI) · recruiting · High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type · principal investigator
- Ph1/Ph2NCT05371054 · Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesNational Cancer Institute (NCI) · completed · Lymphoma, Non-Hodgkin Lymphoma, NHL · principal investigator
- Ph1NCT04739813 · Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaNational Cancer Institute (NCI) · active not recruiting · Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma · principal investigator
- Ph2NCT04002947 · Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaNational Cancer Institute (NCI) · recruiting · Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL · principal investigator
- Ph2NCT03258567 · Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasNational Cancer Institute (NCI) · recruiting · Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder · principal investigator
- Ph1/Ph2NCT03223610 · Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaNational Cancer Institute (NCI) · recruiting · Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma · principal investigator
- N/ANCT01676805 · Tissue Collection for Studies of Lymph CancerNational Cancer Institute (NCI) · recruiting · Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma · principal investigator
- Ph2NCT00005780 · Chemotherapy Plus Vaccination to Treat Mantle Cell LymphomaNational Cancer Institute (NCI) · completed · Mantle Cell Lymphoma, Lymphoma, Mantle Cell · principal investigator
- Ph2NCT00001379 · Treatment and Natural History Study of Lymphomatoid GranulomatosisNational Cancer Institute (NCI) · completed · Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT06649812
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.